Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Dyne Therapeutics, Inc. has received an average rating of "Buy" from sixteen brokerages, with the average 12-month price target set at $34.06.
• CEO John Cox recently acquired 100,000 shares of Dyne Therapeutics at an average cost of $9.11 per share, significantly increasing his ownership stake in the company.
• Institutional investors own 96.68% of Dyne Therapeutics' stock, with notable increases from firms like Hsbc Holdings and Comerica Bank during the fourth quarter.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been given an average recommendation of "Buy" by the sixteen brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $34.0667.

A number of analysts have weighed in on DYN shares. Guggenheim restated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 target price on the stock. Raymond James Financial upgraded Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $31.00 to $35.00 in a research note on Monday, August 25th. Royal Bank Of Canada dropped their price target on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 29th. Finally, Chardan Capital reduced their price objective on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, July 29th.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the transaction, the chief executive officer owned 199,539 shares in the company, valued at $2,675,817.99. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.14% of the stock is currently owned by company insiders.

Institutional Trading of Dyne Therapeutics

A number of large investors have recently made changes to their positions in DYN. CWM LLC grew its stake in Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company's stock worth $29,000 after buying an additional 1,900 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after acquiring an additional 2,446 shares during the period. Quarry LP purchased a new position in shares of Dyne Therapeutics during the first quarter worth approximately $47,000. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock valued at $91,000 after acquiring an additional 955 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Down 0.8%

Dyne Therapeutics stock traded down $0.10 during trading on Friday, reaching $13.18. The stock had a trading volume of 1,669,681 shares, compared to its average volume of 2,212,977. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $37.08. The stock has a market cap of $1.87 billion, a PE ratio of -3.41 and a beta of 1.10. The business has a 50 day moving average price of $11.13 and a 200 day moving average price of $11.14.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. On average, analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.